By delivering therapeutic agents like siRNA that targets IκBα, MnNPs can effectively trigger the NF-κB signaling pathway in these macrophages, repolarizing them from a tumor-promoting M2 phenotype to a tumor-fighting M1 phenotype. Here, NFKB1 is linked to neoplasm.